[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 4 sources · 5 days · First seen · Last updated

Atrial fibrillation stroke prevention research

Overview

Clinical research has increasingly supported the use of oral anticoagulants (OAC) for stroke prevention in patients with atrial fibrillation (AF) at intermediate risk.

Initial data from the SINGLE-AF trial indicated that direct oral anticoagulants, such as apixaban and rivaroxaban, reduce the risk of stroke, systemic embolism, major bleeding, and cardiovascular death. A meta-analysis published in JAMA Cardiology further suggested that transcatheter left atrial appendage closure (LAAC) should not be a routine first-line alternative to OAC, as it was associated with a 34% higher risk of ischemic stroke compared to anticoagulation.

Subsequent findings from a 24-month randomized clinical trial involving 1,803 patients in South Korea, published in the New England Journal of Medicine, reinforced these conclusions. The study demonstrated that patients receiving anticoagulant therapy had a 69% lower cumulative risk of major clinical events and a 90% lower risk of ischemic stroke or systemic embolism compared to untreated groups, while maintaining similar major bleeding rates.

Entities

European Society of Cardiology · Severance Cardiovascular Hospital · JAMA Cardiology · New England Journal of Medicine · Yonsei University College of Medicine

Timeline

  1. 10 days ago

    [HEALTH] 2 sources
    Severance Hospital study finds anticoagulants reduce stroke risk in atrial fibrillation patients

    A clinical study from Severance Cardiovascular Hospital shows that anticoagulants reduce stroke and embolism risks by up to 90% in atrial fibrillation patients with intermediate risk levels.

  2. 15 days ago

    [HEALTH] 2 sources
    Oral anticoagulants reduce stroke risk in atrial fibrillation patients

    Clinical studies confirm that oral anticoagulants effectively reduce stroke and mortality risk in intermediate-risk atrial fibrillation patients, while LAAC is not recommended as a first-line alternative.

Sources

consultantlive.com · hin.company · medicaldialogues.in · thebionews.net